PlainBillCongress, translated.Legislation. Context. Public interest.Referred to the Subcommittee on Health.
Congressional Research Service
Version 00 · Introduced in House · Sep 15, 2011
Pharmaceutical Stewardship Act of 2011 - Establishes the National Pharmaceutical Stewardship Organization as a nonprofit private corporation whose board of directors shall be appointed by the Administrator of the Environmental Protection Agency (EPA). Requires the Organization to begin implementation of a certified national pharmaceutical stewardship program within two years.
Requires each manufacturer and brand owner of a drug marketed in the United States to participate in such program or another certified national pharmaceutical stewardship program.
Establishes requirements for program certification, including requirements to: (1) provide a system to facilitate the collection and disposal of any drug that is a household waste, as defined under the Resource Conservation and Recovery Act, that is delivered to the program by an individual in the United States; and (2) collect and dispose of drugs in a manner that is safe and secure, that results in incineration of the drug in accordance with the hazardous waste incineration requirements under the Solid Waste Disposal Act, that protects patient information, and that is accessible and, in the case of a controlled substance, consistent with the Controlled Substances Act. Prohibits programs from imposing fees on individuals for delivery or disposal of a drug.
Showing the opening paragraphs of the official summary.
Establishes a program certification process, including requiring the Administrator to consult with the Administrator of the Drug Enforcement Administration (DEA) on the adequacy of the proposed program's security measures for collection, transportation, and disposal of drugs, disposal systems, and mechanisms for secure tracking and handling. Authorizes the Administrator to suspend certification of a program if necessary to protect the public from imminent danger.
Requires the Director of National Drug Control Policy to establish a campaign to increase public awareness of how drugs may be lawfully disposed consistent with public safety, public health, and environmental protection.
Requires the Administrator to establish an interagency commission, to be known as the Commission on Drug Disposal and its Public Safety, Public Health, and Environmental Impacts, to develop a strategy to: (1) prevent the entry of drugs into the nation's water supply and environment consistent with current public safety standards, and (2) protect public health and promote public safety by reducing diversion and the risk of abuse and accidental overdose.
Requires the Comptroller General (GAO) to report on drugs and drug byproducts in surface water and groundwater in the United States within a year.
People & committees
Rep. Slaughter, Louise McIntosh [D-NY-28] · D–NY
Legislative record
A procedural vote is different from passage. Passage in one chamber does not establish enactment. Explore the glossary.
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsor introductory remarks on measure. (CR E1639-1640)
Introduced in House
Introduced in House
Primary sources
Text links open the official source. We currently store references to these documents.
No related bills are listed in this snapshot. This does not establish whether the proposal has appeared in earlier Congresses.
Source last updated: Aug 14, 2025. Consult Congress.gov for the current record.
AI Conversation Starters
Choose a perspective, copy a prompt, and paste it into your preferred AI. Each prompt includes the bill version and available official source links, and asks for counterarguments as well as supporting evidence.
Analyze H.R.2939 as objectively as possible. Explain its main provisions, who would be affected, possible benefits and harms, implementation, exceptions, and uncertainties. Present the strongest arguments for and against it, and identify evidence needed to assess its public impact.
Examine H.R.2939 through a progressive lens, focusing on fairness, access, economic inequality, and effects on vulnerable communities. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and distinguish stated goals from demonstrated outcomes.
Examine H.R.2939 through a conservative lens, focusing on fiscal responsibility, institutional stability, federalism, and the scope of government. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and any provisions that challenge this perspective.
Examine H.R.2939 through a civil-liberties and limited-government lens. Consider individual rights, privacy, voluntary choice, accountability, and government power. Explain tradeoffs, possible safeguards, and the strongest counterarguments without assuming the proposal is beneficial or harmful.